This inventor holds 31 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Astrazeneca Ab. Active years: 2005-2024.
Location History:
- Leics, GB (2005)
- Loughborough, GB (2005 - 2011)
- Moindal, SE (2015)
- Mölndal, SE (2014 - 2018)
- Macclesfield, GB (2018 - 2021)
- Cheshire, GB (2016 - 2024)
Company Filing History:
Years Active: 2005-2024
Areas of Expertise:
Title: The Innovative Contributions of Stephen Connolly in the Pharmaceutical Field
Introduction
Stephen Connolly, located in Cheshire, GB, is an accomplished inventor with an impressive portfolio of 31 patents. His innovative work primarily focuses on pharmaceutical compounds, specifically those that target critical medical conditions. With a rich background in drug development, Connolly has made significant contributions to the field, particularly in the treatment of respiratory diseases.
Latest Patents
Among Connolly's notable inventions are his latest patents involving certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides, which act as dipeptidyl peptidase 1 (DPP1) inhibitors. These compounds, including their pharmaceutically acceptable salts, have demonstrated potential in inhibiting DPP1 activity, offering a promising avenue for the treatment and prevention of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). His work encompasses both the therapeutic applications of these compounds and the processes associated with their preparation and utilization in pharmaceutical compositions.
Career Highlights
Connolly currently works at AstraZeneca AB, a leading global pharmaceutical company known for its dedication to scientific innovation and the development of new medications. His extensive experience in the industry is reflected through his multiple patents, which underscore his expertise in drug design and development.
Collaborations
Throughout his career, Connolly has collaborated with noteworthy colleagues such as Steven Swallow and Carl-Johan Aurell. These partnerships have fostered an environment of innovation and creativity, enabling the development of groundbreaking solutions in the pharmaceutical sector.
Conclusion
Stephen Connolly's contributions to the field of pharmaceuticals through his 31 patents showcase his commitment to advancing medical treatments. His latest inventions targeting respiratory diseases exemplify the impactful work he continues to pursue at AstraZeneca AB. As he collaborates with esteemed colleagues, Connolly remains a significant figure in the realm of pharmaceutical innovation, paving the way for future advancements in healthcare.